These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6385263)

  • 21. Mitoxantrone in acute lymphoblastic leukemia.
    Paciucci PA; Ohnuma T; Cuttner J; Silver RT; Holland JF
    Cancer Treat Rev; 1983 Dec; 10 Suppl B():65-8. PubMed ID: 6581869
    [No Abstract]   [Full Text] [Related]  

  • 22. Mitoxantrone in patients with acute leukemia in relapse.
    Paciucci PA; Ohnuma T; Cuttner J; Silver RT; Holland JF
    Cancer Res; 1983 Aug; 43(8):3919-22. PubMed ID: 6861154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitoxantrone in the treatment of acute leukemia.
    Vorobiof DA; Falkson G; Coccia-Portugal MA; Terblanche AP
    Invest New Drugs; 1987 Dec; 5(4):383-8. PubMed ID: 3481364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of remission in acute promyelocytic leukemia with mitoxantrone.
    Mittelman A; Rieber E; Friedland ML; Arlin ZA
    Cancer Chemother Pharmacol; 1985; 14(1):81-2. PubMed ID: 3855290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Phase II study of mitoxantrone for hematologic malignancies].
    Ueoka H; Ueno K; Yamane T; Toyoda K; Endo H; Nishihara R; Takahashi I; Ohnoshi T; Kitajima K; Kimura I
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2399-402. PubMed ID: 6639101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A phase III study of BHAC-MMP (behenoyl-ara-C, mitoxantrone, 6-mercaptopurine prednisolone) in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders].
    Masaoka T; Shibata H; Nagai K; Kanamaru A; Horiuchi A; Kitani T; Yonezawa T; Kawagoe H; Yasunaga K
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2829-34. PubMed ID: 3530140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Phase II study of mitoxantrone for acute leukemia].
    Oguma S; Tatsumi Y; Hirayama F; Tani Y; Kubota Y; Kanakura Y; Ueda T; Nakamura H; Shibata H; Masaoka T
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):497-501. PubMed ID: 6703723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitoxantrone and VP-16 in refractory acute myelogenous leukemia.
    Ho AD; Lipp T; Ehninger G; Meyer P; Rückle H; Steinke B; Kaboth W; Körbling M
    Onkologie; 1986 Jun; 9(3):148-50. PubMed ID: 3528961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
    Ogawa M
    Gan To Kagaku Ryoho; 1986 May; 13(5):1829-36. PubMed ID: 3754711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia.
    Larson RA; Daly KM; Choi KE; Han DS; Sinkule JA
    J Clin Oncol; 1987 Mar; 5(3):391-7. PubMed ID: 3546616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitoxantrone: a new anticancer drug with significant clinical activity.
    Shenkenberg TD; Von Hoff DD
    Ann Intern Med; 1986 Jul; 105(1):67-81. PubMed ID: 3521429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
    Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of mitozantrone in the treatment of acute leukaemia.
    Prentice HG
    Acta Haematol; 1987; 78 Suppl 1():136-8. PubMed ID: 3124436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia.
    Vredenburgh JJ; McIntyre OR; Cornwell GG; Ball ED; Cornell CJ; Mills LE; O'Donnell JF
    Med Pediatr Oncol; 1988; 16(3):187-9. PubMed ID: 3380061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The design, synthesis and development of a new class of potent antineoplastic anthraquinones.
    Cheng CC; Zee-Cheng RK
    Prog Med Chem; 1983; 20():83-118. PubMed ID: 6356227
    [No Abstract]   [Full Text] [Related]  

  • 38. [Mitoxantrone--a new cytostatic agent].
    Klein HO
    Fortschr Med; 1985 Feb; 103(8):229-30. PubMed ID: 3979939
    [No Abstract]   [Full Text] [Related]  

  • 39. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
    Holmes FA; Yap HY; Esparza L; Buzdar AU; Hortobagyi GN; Blumenschein GR
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):28-31. PubMed ID: 6385262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of mitoxantrone in refractory acute leukemia.
    Estey EH; Keating MJ; McCredie KB; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1983 Apr; 67(4):389-90. PubMed ID: 6850655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.